Annemieke S Littooij1,2, Thomas C Kwee1, Bart de Keizer1, Marrie C A Bruin3, Ana Coma4, Frederik J A Beek1, Rob Fijnheer5, Rutger A J Nievelstein1. 1. Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. 2. Department of Diagnostic and Interventional Imaging, KK Women's and Children's Hospital, Singapore. 3. Department of Paediatric Haematology-Oncology, University Medical Centre Utrecht/Wilhelmina Children's Hospital, Utrecht, The Netherlands. 4. Department of Paediatric Radiology, Hospital Materno-Infantil Vall d'Hebron, P. de la Vall d'Hebron, Barcelona, Spain. 5. Department of Haematology, Meander Medical Center, Amersfoort, The Netherlands.
Abstract
BACKGROUND: To assess the performance of whole-body MRI including diffusion-weighted imaging (whole-body MRI-DWI) for the detection of residual disease after completion of treatment in lymphoma patients. METHODS: Twenty-six patients with lymphoma prospectively underwent whole-body MRI-DWI (1.5 Tesla MR) and 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)/computed tomography (CT) for posttreatment evaluation which were visually assessed. Apparent diffusion coefficient (ADC) and FDG-PET/CT standardized uptake value measurements were performed in all residual lesions. An unblinded expert panel reviewed all cases and determined the presence or absence of posttreatment residual disease using all available imaging (except for whole-body MRI-DWI), clinical, and histopathological information with a follow-up of at least 6 months. The performance of whole-body MRI-DWI was compared with this panel reference standard. RESULTS: Five of 26 patients were diagnosed with residual disease. Sensitivity and specificity for detection of residual disease with whole-body MRI-DWI were 100% and 62%, respectively. By ROC analysis, the optimal threshold of ADC was 1.21 × 10(-3) mm(2) /s with sensitivity and specificity of 100% and 91.7%, respectively. CONCLUSION: Our initial results suggest that visual whole-body MRI-DWI analysis has a very good sensitivity for detecting viable residual lesions after completion of therapy but lacks specificity. ADC measurements could potentially increase the specificity of whole-body MRI.
BACKGROUND: To assess the performance of whole-body MRI including diffusion-weighted imaging (whole-body MRI-DWI) for the detection of residual disease after completion of treatment in lymphomapatients. METHODS: Twenty-six patients with lymphoma prospectively underwent whole-body MRI-DWI (1.5 Tesla MR) and 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)/computed tomography (CT) for posttreatment evaluation which were visually assessed. Apparent diffusion coefficient (ADC) and FDG-PET/CT standardized uptake value measurements were performed in all residual lesions. An unblinded expert panel reviewed all cases and determined the presence or absence of posttreatment residual disease using all available imaging (except for whole-body MRI-DWI), clinical, and histopathological information with a follow-up of at least 6 months. The performance of whole-body MRI-DWI was compared with this panel reference standard. RESULTS: Five of 26 patients were diagnosed with residual disease. Sensitivity and specificity for detection of residual disease with whole-body MRI-DWI were 100% and 62%, respectively. By ROC analysis, the optimal threshold of ADC was 1.21 × 10(-3) mm(2) /s with sensitivity and specificity of 100% and 91.7%, respectively. CONCLUSION: Our initial results suggest that visual whole-body MRI-DWI analysis has a very good sensitivity for detecting viable residual lesions after completion of therapy but lacks specificity. ADC measurements could potentially increase the specificity of whole-body MRI.
Authors: Arash Latifoltojar; Shonit Punwani; Andre Lopes; Paul D Humphries; Maria Klusmann; Leon Jonathan Menezes; Stephen Daw; Ananth Shankar; Deena Neriman; Heather Fitzke; Laura Clifton-Hadley; Paul Smith; Stuart A Taylor Journal: Eur Radiol Date: 2018-06-15 Impact factor: 5.315
Authors: Valentina Brancato; Marco Aiello; Roberta Della Pepa; Luca Basso; Nunzia Garbino; Emanuele Nicolai; Marco Picardi; Marco Salvatore; Carlo Cavaliere Journal: Diagnostics (Basel) Date: 2020-09-16
Authors: Jürgen F Schäfer; Claudio Granata; Thekla von Kalle; Martin Kyncl; Annemieke S Littooij; Pier Luigi Di Paolo; Irmina Sefic Pasic; Rutger A J Nievelstein Journal: Pediatr Radiol Date: 2020-05-28
Authors: Suzanne Spijkers; Annemieke S Littooij; Thomas C Kwee; Nelleke Tolboom; Auke Beishuizen; Marrie C A Bruin; Goya Enríquez; Constantino Sábado; Elka Miller; Claudio Granata; Charlotte de Lange; Federico Verzegnassi; Bart de Keizer; Rutger A J Nievelstein Journal: Eur Radiol Date: 2021-05-22 Impact factor: 5.315